Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

In this study, researchers reviewed literature on topical delivery of finasteride for androgenetic alopecia, finding that liposomal gels with specific additives showed the highest skin permeation rates, suggesting potential for reducing systemic side effects compared to oral formulations.

In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.

This source highlights topical minoxidil as the first-line treatment for androgenetic alopecia in both genders and finasteride for men, while also identifying dutasteride, low-dose oral minoxidil, and topical finasteride as promising future options.

This study found that a combination of oral finasteride and topical minoxidil improved the frontal hair line in men with androgenetic alopecia more effectively than either treatment alone.

This review explores current therapeutic options for frontal fibrosing alopecia, noting the use of finasteride, topical tacrolimus, hydroxychloroquine, and excimer laser in managing the condition, but reports no new clinical results.

In this study of female pattern hair loss, oral finasteride 5 mg and topical minoxidil 5% both significantly improved hair density and patient satisfaction over 6 months, outperforming finasteride 2 mg, which showed limited improvement beyond the third month. All treatments were deemed safe.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

This case report describes a patient with advanced androgenetic alopecia who underwent a 6-month trial of topical minoxidil and oral finasteride, aiming to optimize hair regrowth without surgery.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This study found that using gallate-containing formulations like EGCG or tannic acid increased the solubility and controlled release of finasteride in microspheres, enhancing its dermal penetration in pig skin by 10 to 50 times compared to a control.

The topical finasteride spray was safe and well-tolerated with stable effects.

In this study, microneedles combined with finasteride nanostructured lipid carriers (FIN-NLC-MNs) were found to enhance skin penetration and specifically target hair follicles, promoting hair growth and gene regulation in androgenetic alopecia.

This study found that nano-transferosomal gel formulations of finasteride improved its delivery across skin layers, potentially reducing major side effects associated with oral administration for treating male pattern baldness.

This study found that finasteride maintained chemical and physical stability in various excipient mixtures, which may guide the development of stable topical delivery systems.

In this study, the therapeutic response of topical minoxidil solution was not significantly enhanced by adding topical finasteride, questioning its additional value in treating male pattern androgenetic alopecia.

Topical minoxidil showed promise for early male pattern baldness.

Topical minoxidil can help regrow hair.

This study developed a stable, cosmetically appealing formulation for the topical delivery of the peptide FOL-005, enhancing skin permeation and maintaining stability by keeping the peptide solid and in a water-free environment with particle sizes under 10 µm.

Combining topical finasteride with minoxidil significantly improves hair density in treating hair loss.

Minoxidil sulfate, delivered through iontophoresis, can be used to treat hair loss.

In this article, researchers explored the potential of lipidic nanocarriers to enhance the delivery and effectiveness of finasteride in a topical gel form for androgenic alopecia, aiming to improve treatment options and reduce systemic adverse effects.

This study found that finasteride niosomes may enhance hair follicle drug accumulation and promote hair regeneration in androgenetic alopecia mice more effectively than current finasteride formulations.

In this case study, a combination of PRP, topical minoxidil, and topical finasteride showed significantly better results in treating androgenic alopecia than minoxidil alone for a 35-year-old male patient.

This study developed a peptide-based topical delivery system that enhanced hair growth with reduced systemic exposure to finasteride, showing efficacy comparable to 5% minoxidil in vivo while using significantly less finasteride than oral doses.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

This abstract contains no research findings; it comprises website navigation and publication information.

This article discusses finasteride as a treatment for alopecia, noting previous presentations at scientific forums, and reports no new findings.

The two lotions used day and night may be a good alternative to minoxidil for hair loss treatment with better cosmetic effects and tolerance.